Avanos Medical - AVNS Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View AVNS analyst ratings or view top-rated stocks.

2 brokers have issued twelve-month target prices for Avanos Medical's shares. Their AVNS share price forecasts range from $26.00 to $34.00. On average, they predict the company's stock price to reach $29.33 in the next twelve months. This suggests that the stock has a possible downside of 6.4%.
View analysts price targets for AVNS or view top-rated stocks among Wall Street analysts.

Avanos Medical's stock was trading at $27.06 at the beginning of the year. Since then, AVNS stock has increased by 15.8% and is now trading at $31.34.
View the best growth stocks for 2023 here.

Avanos Medical saw a increase in short interest in December. As of December 30th, there was short interest totaling 863,600 shares, an increase of 19.2% from the December 15th total of 724,600 shares. Based on an average daily volume of 224,100 shares, the short-interest ratio is presently 3.9 days. Currently, 1.9% of the shares of the stock are short sold.
View Avanos Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our AVNS earnings forecast.

Avanos Medical, Inc. (NYSE:AVNS) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.27 by $0.02. The firm had revenue of $184.10 million for the quarter, compared to analysts' expectations of $183.90 million. Avanos Medical had a net margin of 5.39% and a trailing twelve-month return on equity of 5.74%. During the same period last year, the business posted $0.21 EPS.

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Avanos Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (1.19%), Heartland Advisors Inc. (0.93%), Pacer Advisors Inc. (0.51%), New York State Teachers Retirement System (0.19%), Thrivent Financial for Lutherans (0.17%) and New York State Common Retirement Fund (0.12%). Insiders that own company stock include Gary Blackford and Patrick J Oleary.
View institutional ownership trends.

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVNS stock can currently be purchased for approximately $31.34.

Avanos Medical (NYSE:AVNS) has a market capitalization of $1.46 billion and generates $744.60 million in revenue each year. The company earns $5.20 million in net income (profit) each year or $0.90 on an earnings per share basis.

The company employs 4,555 workers across the globe.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com.